Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; sodium chloride; polysorbate 80; dibasic sodium phosphate - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; polysorbate 80; water for injections; sodium chloride - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; sodium chloride; dibasic sodium phosphate; water for injections - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections; polysorbate 80 - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: water for injections; monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate; polysorbate 80 - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 40 microgram/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; water for injections; monobasic sodium phosphate monohydrate; polysorbate 80 - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 39.47 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; sodium chloride; dibasic sodium phosphate; polysorbate 80 - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy